Antiviral Remdesivir Approved for Earlier Use For COVID-19 Patients


Remdesivir Received EUA for Use in Patients with Moderate COVID-19

Health Editor’s Note: The antiviral, Remdesivir, Veklury© is now approved for use in the treatment of COVID-19 for all hospitalized patients. A phase 3 trial and an additional NIAID trial have been completed which evaluated remdesivir for use in hospitalized patients with moderate COVID-19 pneumonia. This FDA approval will allow for earlier treatment of patients with COVID-19….Carol



We See The World From All Sides and Want YOU To Be Fully Informed
In fact, intentional disinformation is a disgraceful scourge in media today. So to assuage any possible errant incorrect information posted herein, we strongly encourage you to seek corroboration from other non-VT sources before forming an educated opinion.

About VT - Policies & Disclosures - Comment Policy
Due to the nature of uncensored content posted by VT's fully independent international writers, VT cannot guarantee absolute validity. All content is owned by the author exclusively. Expressed opinions are NOT necessarily the views of VT, other authors, affiliates, advertisers, sponsors, partners, or technicians. Some content may be satirical in nature. All images are the full responsibility of the article author and NOT VT.


  1. The fraudulent war against HCQ by Big Parma Mafia was to introduce this poison which cost 4500 USD per treatment, instead of HCQ 20 USD, well tested by 1000s of doctors worldwide, including my self for at least 100 patients with striking result, but in the first phase of the SARS-COV-2 infection, not in the late pulmonary phase, which all fraudulent so called big pharma studies with deliberately much higher doses were done in inpatients. These hoax studies were meant to fail.
    The biggest scandal of The Lancet came when they retracted their fraudulent anti HCQ article just 2 weeks after publication, after protests by 1000s of doctors to the editor of Lancet. Just one week after this retraction Dr. Professor Harvey Risch published a study in AVJ recommending HQC in earlier phase of infection.

    • Jay, Remdesivir is one of the class of antivirals that pretend to be a building block for the RNA or DNA sequence. this class of antivirals gets included into the genetic part of the viral making process and are able to cause a defective virus. It does not do this to our cells but just harms the virus and messes up the virus’ ability to reproduce. The virus hijacked human cells in order to be able to reproduce more of itself since it does not contain reproductive organs of its own due to the simplicity of the viral cell. Any cells that the coronavirus does produce are defective and cannot invade other cells. Remdesivir is not able to stop all the reproductive activity because it heals itself, but cuts it way down. Remdesivir can only be administered by IV which makes it useable for only those who are in a hospital where an IV can be managed. They are working on an inhaled version but that is not approved yet. So to make a long story shorter, yes it does work to shorten hospital stays but it not 100% effective all the time because the virus is sometimes able to make a work around….

Comments are closed.